首站-论文投稿智能助手
典型文献
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
文献摘要:
The emerging SARS-CoV-2 variants,commonly with many mutations in S1 subunit of spike(S)protein are weakening the efficacy of the current vaccines and antibody therapeutics.This calls for the variant-proof SARS-CoV-2 vaccines targeting the more conserved regions in S protein.Here,we designed a recombinant subunit vaccine,HR121,targeting the conserved HR1 domain in S2 subunit of S protein.HR121 consisting of HR1-linker1-HR2-linker2-HR1,is conformationally and functionally analogous to the HR1 domain present in the fusion intermediate conformation of S2 subunit.Immunization with HR121 in rabbits and rhesus macaques elicited highly potent cross-neutralizing antibodies against SARS-CoV-2 and its variants,particularly Omicron sublineages.Vaccination with HR121 achieved near-full protections against prototype SARS-CoV-2 infection in hACE2 transgenic mice,Syrian golden hamsters and rhesus macaques,and effective protection against Omicron BA.2 infection in Syrian golden hamsters.This study demonstrates that HR121 is a promising candidate of variant-proof SARS-CoV-2 vaccine with a novel conserved target in the S2 subunit for application against current and future SARS-CoV-2 variants.
文献关键词:
作者姓名:
Wei Pang;Ying Lu;Yan-Bo Zhao;Fan Shen;Chang-Fa Fan;Qian Wang;Wen-Qiang He;Xiao-Yan He;Ze-Kai Li;Tao-Tao Chen;Cui-Xian Yang;You-Zhi Li;Si-Xuan Xiao;Zu-Jiang Zhao;Xu-Sheng Huang;Rong-Hua Luo;Liu-Meng Yang;Mi Zhang;Xing-Qi Dong;Ming-Hua Li;Xiao-Li Feng;Qing-Cui Zhou;Wang Qu;Shibo Jiang;Songying Ouyang;Yong-Tang Zheng
作者机构:
Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province,KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China;University of the Chinese Academy of Sciences,Beijing,China;The Key Laboratory of Innate Immune Biology of Fujian Province,Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation,Biomedical Research Center of South China,Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education,College of Life Sciences,Fujian Normal University,Fuzhou,Fujian,China;Division of Animal Model Research,Institute for Laboratory Animal Resources,National Institutes for Food and Drug Control,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,School of Basic Medical Sciences,Fudan University,Shanghai,China;Yunnan Provincial Infectious Disease Hospital,Kunming,Yunnan,China;Kunming National High-level Biosafety Research Center for Non-human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China
引用格式:
[1]Wei Pang;Ying Lu;Yan-Bo Zhao;Fan Shen;Chang-Fa Fan;Qian Wang;Wen-Qiang He;Xiao-Yan He;Ze-Kai Li;Tao-Tao Chen;Cui-Xian Yang;You-Zhi Li;Si-Xuan Xiao;Zu-Jiang Zhao;Xu-Sheng Huang;Rong-Hua Luo;Liu-Meng Yang;Mi Zhang;Xing-Qi Dong;Ming-Hua Li;Xiao-Li Feng;Qing-Cui Zhou;Wang Qu;Shibo Jiang;Songying Ouyang;Yong-Tang Zheng-.A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein)[J].细胞研究(英文版),2022(12):1068-1085
A类:
HR121,linker1,linker2,conformationally,Syrian
B类:
proof,SARS,CoV,targeting,domain,S2,subunit,spike,protein,emerging,variants,commonly,many,mutations,S1,are,weakening,efficacy,current,vaccines,antibody,therapeutics,This,calls,more,conserved,regions,Here,designed,recombinant,consisting,HR2,functionally,analogous,present,fusion,intermediate,Immunization,rabbits,rhesus,macaques,elicited,highly,potent,cross,neutralizing,antibodies,against,particularly,Omicron,sublineages,Vaccination,achieved,near,full,protections,prototype,infection,hACE2,transgenic,mice,golden,hamsters,effective,BA,study,demonstrates,that,promising,candidate,novel,application,future
AB值:
0.434015
相似文献
Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID?19 in a Han Chinese population from Central China
Yi Wu;Xian‑Hui Wang;Xi‑Hua Li;Li‑Yuan Song;Shi‑Long Yu;Zhi‑Cheng Fang;Yu‑Quan Liu;Le‑Yong Yuan;Chun‑Yan Peng;Shen‑Yi Zhang;Wang Cheng;Hong‑Chao Ma;Li‑Feng Wang;Jun‑Ming Tang;Yun‑Fu Wang;Fu‑Yun Ji-Department of Medical Biology,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Biomedical Research,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Human Respiratory Disease,Xinqiao Hospital,The Army Medical University(Third Military Medical University),400037 Chongqing,China;Department of Emergency Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Geriatric Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Immunology,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Laboratory Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Hubei Key Laboratory of Embryonic Stem Cell Research,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Neurology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
Xiao-Li Feng;Dandan Yu;Mi Zhang;Xiaohong Li;Qing-Cui Zou;Wentai Ma;Jian-Bao Han;Ling Xu;Cuixian Yang;Wang Qu;Zhong-Hua Deng;Junyi Long;Yanghaopeng Long;Mingkun Li;Yong-Gang Yao;Xing-Qi Dong;Jianxiong Zeng;Ming-Hua Li-Kunming National High-level Biosafety Research Center for Non-Human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650107,China;Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences,and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650201,China;National Resource Center for Non-Human Primates,National Research Facility for Phenotypic&Genetic Analysis of Model Animals(Primate Facility),Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming 650107,China;Department of Infectious Diseases,Yunnan Provincial Infectious Diseases Hospital,Kunming,650301,China;Key Laboratory of Genomic and Precision Medicine,Beijing Institute of Genomics,Chinese Academy of Sciences,and China National Center for Bioinformation,Beijing,100101,China;University of Chinese Academy of Sciences,Beijing,100049,China;Center for Excellence in Animal Evolution and Genetics,Chinese Academy of Sciences,Kunming,650201,China;Kunming College of Life Science,University of Chinese Academy of Sciences,Kunming 650204,China;Yunnan Key Laboratory of Biodiversity Information,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,650201,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Structures of SARS-CoV-2 spike protein alert noteworthy sites for the potential approaching variants
Xiaorui Xing;Lei Wang;Zhen Cui;Wangjun Fu;Tao Zheng;Lili Qin;Pingju Ge;Aidong Qian;Nan Wang;Shuai Yuan-College of Veterinary Medicine,Jilin Agricultural University,Changchun,130118,China;College of Animal Science and Technology,Jilin Provincial Engineering Research Center of Animal Probiotics,Key Lab of Animal Production,Product Quality and Security,Joint Laboratory of Modern Agricultural Technology International Cooperation,Ministry of Education,Jilin Agricultural University,Changchun,130118,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;University of Chinese Academy of Sciences,Beijing 100101,China;Acrobiosystems,Beijing,100101,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。